Germany's Boehringer Ingelheim is pursuing a policy that emphasizes long-term perspectives and early-stage development and strategy, supported by the advantages of being privately held. This article reports on comments made by Shashank Deshpande in an interview during his visit to Japan.
Germany's major pharmaceutical company Boehringer Ingelheim (BI) is regarded as the only privately held company among global pharmaceutical companies. In an industry requiring substantial research and development investment, the advantages of being privately held and the strategic implications are being reconsidered.
BI has indicated a policy of emphasizing a long-term perspective and an early-stage approach. In an interview with Shashank Deshpande, chairman of the Board of Managing Directors and member of the Board of Managing Directors responsible for the Human Pharma business, during his visit to Japan, the company explained this approach in concrete terms.
The article describes the company's willingness to discuss the redistribution of burdens with governments in various countries on global issues, including its response to the MFN drug pricing policy. Deshpande emphasized the importance of the flexibility and long-term strategy afforded by being a privately held company.